Glaxo Ziagen/Agenerase
Executive Summary
Viral loads of less than five copies/mL were achieved by 48 weeks in 39% of patients (16/41) treated with a combination regimen of Agenerase (amprenavir) and Ziagen (abacavir) and 47% of patients (19/40) by week 72, a Phase II study evaluating early stage HIV-positive individuals treated with the two-drug combination demonstrated. The study presented at ICAAC also observed that the CD4 cell count of 41 Agenerase/Ziagen treated individuals increased from a baseline count of 756 to 878 at week 24. In comparison, HIV-negative patients maintained a count of 967 CD4 cells
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth